[1] PEGTEL DM, GOULD SJ. Exosomes. Annu Rev Biochem. 2019;88:487-514.
[2] YU B, ZHANG X, LI X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci. 2014;15(3):4142-4157.
[3] ZHANG Y, YU M, TIAN W. Physiological and pathological impact of exosomes of adipose tissue. Cell Prolif. 2016;49(1):3-13.
[4] RAPOSO G, STOORVOGEL W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373-383.
[5] KOOIJMANS SAA, FLIERVOET LAL, VAN DER MEEL R, et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release. 2016;224:77-85.
[6] LI S, WU Y, DING F, et al. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale. 2020;12(19):10854-10862.
[7] MILBANK E, DRAGANO NRV, GONZALEZ-GARCIA I, et al. Small extracellular vesicle-mediated targeting of hypothalamic AMPKalpha1 corrects obesity through BAT activation. Nat Metab. 2021;3(10):1415-1431.
[8] FUHRMANN G, SERIO A, MAZO M, et al. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2015;205:35-44.
[9] ALVAREZ-ERVITI L, SEOW Y, YIN H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29(4):341-345.
[10] XU X, LIANG Y, LI X, et al. Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials. 2021;269:120539.
[11] XU F, FEI Z, DAI H, et al. Mesenchymal stem cell-derived extracellular vesicles with high pd-l1 expression for autoimmune diseases treatment. Adv Mater. 2021:e2106265.
[12] PATTON MC, ZUBAIR H, KHAN MA, et al. Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival. J Cell Biochem. 2020;121(1):828-839.
[13] PASCUCCI L, COCCÈ V, BONOMI A, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014;192:262-270.
[14] DIDIOT MC, HALL LM, COLES AH, et al. Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol Ther. 2016;24(10):1836-1847.
[15] KIM S, KANG JH, NGUYEN CAO TG, et al. Extracellular vesicles with high dual drug loading for safe and efficient combination chemo-phototherapy. Biomater Sci. 2022;10(11):2817-2830.
[16] RAGHAV A, JEONG GB. A systematic review on the modifications of extracellular vesicles: a revolutionized tool of nano-biotechnology. J Nanobiotechnology. 2021;19(1):459.
[17] DU J, WAN Z, WANG C, et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. Theranostics. 2021;11(17):8185-8196.
[18] MOMEN-HERAVI F, BALA S, BUKONG T, et al. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine. 2014;10(7):1517-1527.
[19] KOOIJMANS SAA, STREMERSCH S, BRAECKMANS K, et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J Control Release. 2013; 172(1):229-238.
[20] HOOD JL, SCOTT MJ, WICKLINE SA. Maximizing exosome colloidal stability following electroporation. Anal Biochem. 2014;448:41-49.
[21] DUMONTEL B, SUSA F, LIMONGI T, et al. Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices. Cell Biosci. 2022;12(1):61.
[22] HANEY MJ, KLYACHKO NL, ZHAO Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release. 2015;207: 18-30.
[23] CIECHOMSKA IA, TOLKOVSKY AM. Non-autophagic GFP-LC3 puncta induced by saponin and other detergents. Autophagy. 2007;3(6): 586-590.
[24] HETTICH BF, BADER JJ, LEROUX JC. Encapsulation of hydrophilic compounds in small extracellular vesicles: loading capacity and impact on vesicle functions. Adv Healthc Mater. 2022;11(5):e2100047.
[25] GOH WJ, LEE CK, ZOU S, et al. Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy. Int J Nanomedicine. 2017;12:2759-2767.
[26] WANG M, LV CY, LI SA, et al. Near infrared light fluorescence imaging-guided biomimetic nanoparticles of extracellular vesicles deliver indocyanine green and paclitaxel for hyperthermia combined with chemotherapy against glioma. J Nanobiotechnology. 2021;19(1):210.
[27] TIAN T, ZHANG H X, HE CP, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018;150:137-149.
[28] KADDOUR H, PANZNER TD, WELCH JL, et al. Electrostatic surface properties of blood and semen extracellular vesicles: implications of sialylation and HIV-induced changes on EV internalization. Viruses. 2020;12(10):1117.
[29] TAMURA R, UEMOTO S, TABATA Y. Augmented liver targeting of exosomes by surface modification with cationized pullulan. Acta Biomater. 2017;57:274-284.
[30] FROHLICH E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7: 5577-5591.
[31] ZHAN Q, YI K, QI H, et al. Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy. Theranostics. 2020;10(17):7889-7905.
[32] SHEN J, HU Y, PUTT K S, et al. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget. 2018;9(4):4485-4495.
[33] FENG C, XIONG Z, WANG C, et al. Folic acid-modified Exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis. Bioact Mater. 2021;6(4):963-974.
[34] LOU G, CHEN L, XIA C, et al. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. J Exp Clin Cancer Res. 2020;39(1):4.
[35] QIAO L, HU S, HUANG K, et al. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. Theranostics. 2020;10(8):3474-3487.
[36] ZHOU W, ZHOU Y, CHEN X, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268:120546.
[37] LAI RC, ARSLAN F, LEE MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4(3): 214-222.
[38] GRAY W D, FRENCH K M, GHOSH-CHOUDHARY S, et al. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res. 2015;116(2): 255-263.
[39] YOUN SW, LI Y, KIM YM, et al. Modification of cardiac progenitor cell-derived exosomes by miR-322 provides protection against myocardial infarction through Nox2-dependent angiogenesis. Antioxidants (Basel). 2019;8(1):18.
[40] WANG Q, ZHANG L, SUN Z, et al. HIF-1alpha overexpression in mesenchymal stem cell-derived exosome-encapsulated arginine-glycine-aspartate (RGD) hydrogels boost therapeutic efficacy of cardiac repair after myocardial infarction. Mater Today Bio. 2021;12:100171.
[41] ZHA Y, LI Y, LIN T, et al. Progenitor cell-derived exosomes endowed with VEGF plasmids enhance osteogenic induction and vascular remodeling in large segmental bone defects. Theranostics. 2021;11(1):397-409.
[42] WOO CH, KIM HK, JUNG GY, et al. Small extracellular vesicles from human adipose-derived stem cells attenuate cartilage degeneration. J Extracell Vesicles. 2020;9(1):1735249.
[43] LIANG Y, XU X, LI X, et al. Chondrocyte-targeted microRNA delivery by engineered exosomes toward a cell-free osteoarthritis therapy. ACS Appl Mater Interfaces. 2020;12(33):36938-36947.
[44] SUN D, ZHUANG X, XIANG X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18(9):1606-1614.
[45] ZHUANG X, XIANG X, GRIZZLE W, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther. 2011;19(10):1769-1779.
[46] RIAZIFAR M, MOHAMMADI MR, PONE EJ, et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano. 2019;13(6):6670-6688.
[47] TIEU A, LALU MM, SLOBODIAN M, et al. An analysis of mesenchymal stem cell-derived extracellular vesicles for preclinical use. ACS Nano. 2020;14(8):9728-9743.
[48] KOK VC, YU CC. Cancer-derived exosomes: their role in cancer biology and biomarker development. Int J Nanomedicine. 2020;15:8019-8036.
[49] CAO L, TIAN T, HUANG Y, et al. Neural progenitor cell-derived nanovesicles promote hair follicle growth via miR-100. J Nanobiotechnol. 2021;19(1):20.
[50] STAUBACH S, BAUER FN, TERTEL T, et al. Scaled preparation of extracellular vesicles from conditioned media. Adv Drug Deliv Rev. 2021;177:113940.
[51] BOST JP, SAHER O, HAGEY D, et al. Growth media conditions influence the secretion route and release levels of engineered extracellular vesicles. Adv Healthc Mater. 2021;11(5):e2101658.
[52] LI S, XU J, QIAN J, et al. Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation. Biomater Sci. 2020;8(24):6978-6991.
[53] ROHDE E, PACHLER K, GIMONA M. Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing. Cytotherapy. 2019;21(6):581-592.
[54] MUNAGALA R, AQIL F, JEYABALAN J, et al. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 2016;371(1):48-61.
[55] FREITAS D, BALMANA M, POCAS J, et al. Different isolation approaches lead to diverse glycosylated extracellular vesicle populations. J Extracell Vesicles. 2019;8(1):1621131.
[56] GERCEL-TAYLOR C, ATAY S, TULLIS RH, et al. Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. Anal Biochem. 2012;428(1):44-53.
[57] GÖRGENS A, BREMER M, FERRER-TUR R, et al. Optimisation of imaging flow cytometry for the analysis of single extracellular vesicles by using fluorescence-tagged vesicles as biological reference material. J Extracell Vesicles. 2019;8(1):1587567.
[58] KREIMER S, BELOV AM, GHIRAN I, et al. Mass-spectrometry-based molecular characterization of extracellular vesicles: lipidomics and proteomics. J Proteome Res. 2015;14(6):2367-2384.
[59] VULTO AG, JAQUEZ OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford). 2017;56(suppl_4):iv14-iv29.
[60] PATEL DB, GRAY KM, SANTHARAM Y, et al. Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell-derived extracellular vesicles. Bioeng Transl Med. 2017;2(2):170-179.
[61] IANCU EM, KANDALAFT LE. Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting. Curr Opin Biotechnol. 2020;65:233-241.
[62] BHATIA SN, CHEN X, DOBROVOLSKAIA MA, et al. Cancer nanomedicin. Nat Rev Cancer. 2022;8:1-7.
[63] DE JONG OG, KOOIJMANS SAA, MURPHY DE, et al. Drug delivery with extracellular vesicles: from imagination to innovation. Acc Chem Res. 2019;52(7):1761-1770.
[64] DEVILLE S, BERCKMANS P, VAN HOOF R, et al. Comparison of extracellular vesicle isolation and storage methods using high-sensitivity flow cytometry. PLoS One. 2021;16(2):e0245835.
[65] PAGANINI C, CAPASSO PALMIERO U, POCSFALVI G, et al. Scalable production and isolation of extracellular vesicles: available sources and lessons from current industrial bioprocesses. Biotechnol J. 2019; 14(10):e1800528.
[66] LORINCZ AM, TIMAR CI, MAROSVARI KA, et al. Effect of storage on physical and functional properties of extracellular vesicles derived from neutrophilic granulocytes. J Extracell Vesicles. 2014;3:25465.
[67] WU K, HE C, WU Y, et al. Preservation of small extracellular vesicle in gelatin methacryloyl hydrogel through reduced particles aggregation for therapeutic applications. Int J Nanomedicine. 2021;16:7831-7846.
[68] CHAROENVIRIYAKUL C, TAKAHASHI Y, NISHIKAWA M, et al. Preservation of exosomes at room temperature using lyophilization. Int J Pharm. 2018;553(1-2):1-7.
[69] HERRMANN IK, WOOD MJA, FUHRMANN G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021; 16(7):748-759.
[70] LENER T, GIMONA M, AIGNER L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087.
[71] KASPI H, SEMO J, ABRAMOV N, et al. MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model. Stem Cell Res Ther. 2021;12(1):72.
[72] DONG J, WU Y, ZHANG Y, et al. Comparison of the therapeutic effect of allogeneic and xenogeneic small extracellular vesicles in soft tissue repair. Int J Nanomedicine. 2020;15:6975-6991.
[73] SHEARN AIU, ADAY S, BEN-AICHA S, et al. Analysis of neat biofluids obtained during cardiac surgery using nanoparticle tracking analysis: methodological considerations. Front Cell Dev Biol. 2020;8:367.
[74] Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. 2020. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes. |